Novel therapeutic approaches in primary hyperoxaluria.

Area of Science:

• Nephrology
• Genetics
• Metabolic Disorders

Background:

• Primary hyperoxaluria (PH) encompasses three types (PH I-III), each stemming from distinct gene mutations impacting liver glyoxylate metabolism.
• PH is characterized by overproduction of endogenous oxalate, leading to elevated urinary oxalate excretion, kidney stones, and nephrocalcinosis.
• Chronic inflammasome activation in PH contributes to kidney function decline, frequently resulting in end-stage renal disease (ESRD), particularly in PH type I.

Purpose of the Study:

• To review current therapeutic strategies for PH, which are primarily supportive, including increased fluid intake and medications like alkaline citrate.
• To provide an overview of ongoing clinical studies and promising research for novel therapeutic approaches in PH.
• To highlight the urgent need for new treatments due to the severe disease burden and progression to ESRD.

Main Methods:

• Searched electronic databases: ClinicalTrials.gov, PubMed.
• Included congress reports, press releases, and personal information from scientific conventions.
• Utilized medical subject headings: primary hyperoxaluria, PH, therapy, treatment, and research.

Main Results:

• Several promising therapeutic agents for PH are under investigation.
• Some agents are in early drug development stages, while others are progressing through clinical trials (Phase I-III).

Conclusions:

• There is significant hope for new treatment options for primary hyperoxaluria becoming available soon.
• Ongoing research and clinical trials indicate a positive outlook for managing PH and its severe consequences.